Olema Pharmaceuticals, Inc.
OLMA
$27.45
$0.301.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.84% | -10.38% | -4.65% | -19.39% | 13.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.95% | 12.93% | 18.86% | 10.69% | 61.17% |
| Operating Income | -21.95% | -12.93% | -18.86% | -10.69% | -61.17% |
| Income Before Tax | -22.17% | -44.11% | 1.88% | -25.38% | -60.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.17% | -44.11% | 1.88% | -25.38% | -60.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.17% | -44.11% | 1.88% | -25.38% | -60.71% |
| EBIT | -21.95% | -12.93% | -18.86% | -10.69% | -61.17% |
| EBITDA | -22.14% | -12.85% | -18.78% | -10.64% | -61.39% |
| EPS Basic | 18.40% | 5.13% | 36.17% | -4.40% | -26.21% |
| Normalized Basic EPS | 18.40% | 26.79% | 23.90% | 5.48% | -26.24% |
| EPS Diluted | 18.40% | 5.13% | 36.17% | -4.40% | -26.21% |
| Normalized Diluted EPS | 18.40% | 26.79% | 23.90% | 5.48% | -26.24% |
| Average Basic Shares Outstanding | 49.72% | 51.91% | 53.72% | 20.10% | 27.32% |
| Average Diluted Shares Outstanding | 49.72% | 51.91% | 53.72% | 20.10% | 27.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |